Dragon Tamer: New Models Needed To Capture China Opportunities
As China enacts reforms to open up to novel drugs, companies must rapidly change their approaches and adopt new business models to seize the window of opportunity, industry insiders tell a recent partnering event in the country.
You may also be interested in...
When China’s e-commerce giant Alibaba flexes its muscles, this time in personalized healthcare using artificial intelligence, everyone takes note.
When a roomful of attendees at the annual ChinaTrials meeting, held Nov. 4 in Beijing, voted that a planned marketing authorization holder (MAH) system would be the single development likely to have the most impact on the pharma industry, few predicted that the scheme would come true just hours later.
After securing the first approval globally for an inhaled COVID-19 vaccine, Chinese biotech CanSino CEO Xuefeng Yu sat down with Scrip in this Chinese-language interview to share his views on vaccine development and market opportunities in China and elsewhere.